Boulder, Colorado - August 23, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patent 7,253,267 by the U.S. Patent and Trademark Office. Joe Cox, Company President commented “This patent provides key intellectual property protection for our long-acting, second generation interleukin-11 (IL-11) analog product. IL-11 is a human protein that stimulates…
Read more
Bolder BioTechnology Receives Continued Grant Support from the National Institutes of Health to Develop Second Generation Infection Fighting Protein
Boulder, Colorado - July 16, 2007 - Bolder BioTechnology, Inc. today announced that it has been awarded a $762,475 Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of The National Institutes of Health. The grant supports research to improve the pharmacological properties of a human protein,…
Read more
Bolder BioTechnology Receives Two U.S. Patents for Second Generation Hematopoietic Factors
Boulder, Colorado - July 16, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patents 7,214,779 and 7,232,885 by the U.S. Patent and Trademark Office. Joe Cox, Company President commented "These patents broaden the scope of intellectual property protection for our long-acting, second generation granulocyte-macrophage colony-stimulating factor (GM-CSF) analog and granulocyte…
Read more
Bolder BioTechnology Receives Two U.S. Patents for Long-Acting GM-CSF Analogs
Boulder, Colorado - January 2, 2007 - Bolder BioTechnology, Inc. is pleased to announce that it has been granted patents 7,148,333 and 7,153,943 by the United States Patent and Trademark Office. Joe Cox, Company President said "These patents provide important intellectual property protection for our long-acting granulocyte-macrophage colony-stimulating factor (GM-CSF) analogs. GM-CSF is a human protein…
Read more